Nature's Sunshine (NATR) Q3 earnings report preview: what to look for

What happened

Nature's Sunshine will report third-quarter results Wednesday afternoon. Last quarter it reported $117 million in revenue, up 1.9% year on year, but missed analyst estimates for revenue, EBITDA and earnings per share. Analysts expect flat revenue this quarter.

Confirmed

Global impact / market context

Flat expected revenue would end the 12% growth seen a year earlier, so investors will focus on whether sales have stalled. Last quarter's misses on profit measures and sales suggest costs or demand may be under pressure, which could weigh on the stock if repeated.

Analyst inference

Peers in personal care give mixed signals: Estée Lauder grew revenue 6.8%, while Medifast fell 19.4%. The article says Medifast traded up 5.2% after topping estimates, suggesting beating expectations can matter more than absolute growth. Analysts recently reconfirmed Nature's Sunshine estimates.

Analyst inference

What to watch

1. Watch whether reported revenue meets the flat year-on-year expectation, since last quarter's $117 million result missed analyst estimates and a second miss could change views on demand. Confirmed
2. Watch whether management gives guidance on future sales and costs; no guidance details appear in the article, so any update would be new information for investors. Proposed
3. Watch EBITDA and earnings per share after last quarter's significant misses; improvement there would suggest better profit per sale, while another miss could pressure the shares. Analyst inference

Evidence

• stockstory.org